These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 28826073)

  • 1. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
    Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
    Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
    Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.
    Nie RC; Chen FP; Yuan SQ; Luo YS; Chen S; Chen YM; Chen XJ; Chen YB; Li YF; Zhou ZW
    Eur J Cancer; 2019 Jan; 106():1-11. PubMed ID: 30453169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
    Dercle L; Ammari S; Champiat S; Massard C; Ferté C; Taihi L; Seban RD; Aspeslagh S; Mahjoubi L; Kamsu-Kom N; Robert C; Marabelle A; Schlumberger M; Soria JC; Postel-Vinay S
    Eur J Cancer; 2016 Sep; 65():33-42. PubMed ID: 27451022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperprogressive disease with anti-PD-1 and anti-PD-L1.
    Brower V
    Lancet Oncol; 2016 Dec; 17(12):e527. PubMed ID: 27866860
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
    Song P; Zhang J; Shang C; Zhang L
    Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.
    Moschetta M; Uccello M; Kasenda B; Mak G; McClelland A; Boussios S; Forster M; Arkenau HT
    Biomed Res Int; 2017; 2017():1506824. PubMed ID: 29318140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.
    Gauci ML; Lanoy E; Champiat S; Caramella C; Ammari S; Aspeslagh S; Varga A; Baldini C; Bahleda R; Gazzah A; Michot JM; Postel-Vinay S; Angevin E; Ribrag V; Hollebecque A; Soria JC; Robert C; Massard C; Marabelle A
    Clin Cancer Res; 2019 Feb; 25(3):946-956. PubMed ID: 30297458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of immune-checkpoint inhibitors in lung cancer.
    Jain P; Jain C; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753465817750075. PubMed ID: 29385894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
    Ameratunga M; Chénard-Poirier M; Moreno Candilejo I; Pedregal M; Lui A; Dolling D; Aversa C; Ingles Garces A; Ang JE; Banerji U; Kaye S; Gan H; Doger B; Moreno V; de Bono J; Lopez J
    Eur J Cancer; 2018 Jan; 89():56-63. PubMed ID: 29227818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.
    Postel-Vinay S; Aspeslagh S; Lanoy E; Robert C; Soria JC; Marabelle A
    Ann Oncol; 2016 Feb; 27(2):214-24. PubMed ID: 26578728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
    Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.